CAR-T Cell Therapy vs TIL Therapy: How They Differ

Both treatments use the patient's own immune cells. Both are given once rather than in cycles. Both belong to the same family of cellular immunotherapy. And yet they are offered to different patients, for different cancers, through very different processes.

Patients often encounter both names while researching options and reasonably assume they are variations of one idea. The distinction matters, because which one applies to you is decided by your diagnosis rather than by preference.

This article sets the two side by side.

In this article

• The core difference


• How each one is made


• Which cancers each treats


• What the process demands of the patient


• Side effects compared


• Frequently asked questions


• Finding out which applies to you

The core difference

The difference comes down to a single question: where does the ability to recognise the cancer come from?

In CAR-T cell therapy, it is added. T-cells are taken from the blood and engineered in a laboratory to carry a receptor aimed at one specific marker — usually CD19 in B-cell cancers. The cells did not recognise the cancer before; the modification gives them that ability.

In TIL therapy, it is already there. Immune cells are taken from inside the tumour itself. They found the cancer on their own, and the laboratory simply grows them into large enough numbers to make a difference.

One approach engineers recognition. The other multiplies recognition that already exists.

How each one is made

CAR-T begins with a blood draw. T-cells are separated out, genetically modified to carry the new receptor, expanded over several weeks and returned in a single infusion.

TIL begins with surgery. A piece of tumour is removed, the immune cells living inside it are isolated, and those showing the strongest response are grown over several weeks before being returned.

That difference — blood draw versus surgery — is one of the most practical distinctions between them. TIL therapy requires tumour tissue that can be safely removed. CAR-T does not.

Which cancers each treats

This is where the two rarely overlap.

CAR-T cell therapy is used for blood cancers: certain lymphomas, leukaemias and myeloma. These cancers grow from B-cells or plasma cells, which carry consistent surface markers such as CD19 or BCMA. A single engineered receptor can therefore find essentially all of the cancer cells.

TIL therapy is used for solid tumours, most established in advanced melanoma. Solid tumours rarely carry a marker that healthy tissue does not also carry, which is precisely why the engineered approach has struggled there — and why using cells that already recognise the tumour makes sense instead.

You can read more on our CAR-T cell therapy and TIL therapy pages.

What the process demands of the patient

Both journeys take several weeks and both include a short course of chemotherapy before the cells are returned, to make room for the new population.

The differences are in what comes before and after. TIL therapy requires a surgical procedure at the start, so surgical fitness is part of eligibility. CAR-T requires only apheresis, which is closer to a long blood donation.

Afterwards, CAR-T patients are monitored intensively in the first weeks for immune reactions, and remain vulnerable to infection for longer because healthy B-cells are also destroyed. TIL patients face a recovery period shaped mainly by the preparative chemotherapy and the supportive treatment given alongside the cells.

Side effects compared

CAR-T carries two effects that are specific to it: cytokine release syndrome, and neurological effects such as confusion or difficulty finding words. Both are usually temporary and treatable, and both are the reason for close monitoring after infusion. Long-term, the loss of healthy B-cells means reduced antibody levels for a period.

TIL side effects come mostly from the preparative chemotherapy — low blood counts, infection risk, fatigue — and from the supportive treatment given with the cells, which can cause fluid retention and low blood pressure.

Neither profile is inherently milder. They are different, and they are managed differently.

Finding out which applies to you

Which of these treatments is relevant depends on your cancer type, what has already been tried, and whether you meet the practical requirements each one carries.

If you would like your records reviewed, contact our team and we will explain what is needed.

This article is general information about cellular immunotherapy. It is not medical advice and does not replace consultation with a qualified physician.